Jump to content

GA²LEN

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dawnseeker2000 (talk | contribs) at 13:08, 28 June 2020 (Typo fixing, date format audit, typo(s) fixed: ’s → 's). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Global Allergy and Asthma European Network
AbbreviationGA²LEN
Parent organization
European Union
Websitewww.ga2len.net

GA²LEN, or Global Allergy and Asthma European Network, is a consortium of leading European research centres specialized in allergic diseases, which include asthma. Funded by the European Union under the 6th Framework Programme, GA²LEN addresses the growing public health concern of allergic diseases.

Research teams were chosen for their scientific excellence, their record on multidisciplinary working and international collaboration, and their educational activities. Since the launch of the Network, it has grown to include an additional 50 collaborating centres making GA²LEN one of the largest multidisciplinary networks of researchers in allergy and asthma worldwide.

Integrating European research

Europe has produced some of the most important recent findings on allergy and asthma, but research tends to be fragmented in different institutes and even in different departments of the same organization. Findings are not always shared nor rapidly translated into changes in practice. The GA²LEN Network of Excellence (NoE) exists to help integrate research activities in Europe and to establish the structure for a European Research Area of excellence in allergy and asthma that will endure.

Spreading knowledge and excellence

The network aims to accelerate the application of research results into clinical practice, to meet the needs of patients, and to help guide policy development. It also aims to promote training and greater integration between public and private sectors in this medical field.

By addressing allergy and asthma in their totality, GA²LEN's ultimate objective is to benefit the well-being of patients by decreasing the burden of allergic diseases in Europe.

Personnel

GA²LEN Publications and Journals

  • Heinzerling, L. M.; Burbach, G. J.; Edenharter, G.; Bachert, C.; Bindslev-Jensen, C.; Bonini, S.; Bousquet, J.; Bousquet-Rouanet, L.; Bousquet, P. J.; Bresciani, M.; Bruno, A.; Burney, P.; Canonica, G. W.; Darsow, U.; Demoly, P.; Durham, S.; Fokkens, W. J.; Giavi, S.; Gjomarkaj, M.; Gramiccioni, C.; Haahtela, T.; Kowalski, M. L.; Magyar, P.; Muraközi, G.; Orosz, M.; Papadopoulos, N. G.; Röhnelt, C.; Stingl, G.; Todo-Bom, A.; von Mutius, E.; Wiesner, A.; Wöhrl, S.; Zuberbier, T. (1 October 2009). "GA2LEN skin test study I: GA²LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe". Allergy. 64 (10): 1498–1506. doi:10.1111/j.1398-9995.2009.02093.x. PMID 19772515.
  • Compalati, E.; Passalacqua, G.; Bonini, M.; Canonica, G. W. (1 November 2009). "The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis". Allergy. 64 (11): 1570–1579. doi:10.1111/j.1398-9995.2009.02129.x. PMID 19796205.

Media

"The allergy epidemic: by 2015 half of us may be carrying one of these" The Guardian, by Sarah Boseley, Health Editor